Elhízás: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• GLP-1 170
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the role of Tbx-3 expressing neurons during obesity and ageing (OBrAgeing)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 2 210 625 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Metabolic disease heterogeneity definition, prevention and remission with targeted interventions (MEDIculous REMeDy)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Németország· EU contribution 4 437 236 EUR· until 2030. dec.· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Svájc· EU contribution 3 885 022 EUR· until 2030. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Modelling endocrine-Immune interactions in response to food Proteins (IMMPRO).

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 194 075 EUR· until 2028. aug.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  A Pan-population study of obesity, risk and metabolic architecture (PANORAMA)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 2 491 440 EUR· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting Cardiovascular Disease with Microbiota-derived Bioactive Compounds (DIETherapy)

  Goeteborgs Universitet· Goeteborg, Svédország· EU contribution 236 340 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unveiling Dynamic Autonomic Regulation in health and disease through Network Physiology (DARNePh)

  Univerzita Komenskeho V Bratislave· Bratislava 1, Szlovákia· EU contribution 172 942 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unique and overlapping functions and CNS sites of action for NK2R and LepR signaling (LINK2CNS)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 423 946 EUR· until 2029. aug.· 2 countries

10 of 127 running projects, newest first. Listed amounts together: 430,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 10
• Mendelian Randomization Analysis 179
• CRISPR-Cas Systems 7
• Gene Expression Profiling 144
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 127
• Metabolomics 190
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 258
• Machine Learning 155
• Deep Learning 20
• Cohort Studies 1013
• Genome-Wide Association Study 202

• Single-cell landscape of human adipose tissue reveals THBS1 as a potential driver of fibro-inflammation in metabolic disease.

  Nat Commun, 2026. okt.

• Single-cell transcriptomics uncovers persistent hepatic immunometabolic remodeling following SARS-CoV-2 infection in obese hosts.

  Front Immunol, 2026. okt.

• Single-cell RNA sequencing reveals a pro-fibrotic epithelial subpopulation contributing to endometrial dysfunction in polycystic ovary syndrome.

  Front Endocrinol (Lausanne), 2026. szept.

• Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.

  Diabetologia, 2026. szept.

• Single-cell profiling identifies obesity-disrupted brain glucose sensing.

  Nat Commun, 2026. aug.

• Female-specific metabolic genetic liability reveals a separable metabolic dimension of polycystic ovary syndrome.

  Mol Cell Endocrinol, 2026. júl.

• Alterations of sphingosine-1-phosphate and its receptors in type 1 diabetes mellitus: an integrated clinical and single-cell transcriptomic study.

  Front Immunol, 2026. jún.

• Temporal single-cell transcriptional dynamics of murine pancreatic islet remodeling during hyperglycaemia progression.

  Mol Metab, 2026. jún.

• Single-Cell Transcriptome-Wide Mendelian Randomization and Colocalization Uncover Potential Immunocytes-Related Therapeutic Targets for Obesity.

  J Cell Mol Med, 2026. máj.

• Adipose single cell epigenome and transcriptome localize genetic risk for cardiometabolic disease and accelerated aging.

  Nat Commun, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.